top of page

Welcome!

The Cancer Discovery Hub (CDH) is a one-stop pan-omics diagnostic and research core laboratory housed at the National Cancer Centre Singapore. We specialise in state-of-the-art research-grade technologies and provide expert support to investigators on all cancer related projects.

Home: Welcome

Latest news

Key events and achievements

  • 10 Nov 2025 : Collaborative research agreement with 10X Genomics

  • 08 July 2025 : Collaborative research agreement with Remission Biotech

  • 25 April 2025: Poster Presentations, AACR Annual Meeting, Chicago, USA (Jing Yi Lee, Bavani Kannan)

  • 07 Dec 2024: Poster Presentations, ASH Annual Meeting, New Orleans, USA

  • 11 Oct 2024 : MOU signed with DxD Hub, A*STAR; Collaborative research agreement with PacBio and KITKOJI

  • 14 June 2024 : Poster Presentations, EHA Congress, Madrid, Spain (Boon Yee Lim) 

  • 10 April 2024 : Poster Presentations + Scholar-in-Training Award, AACR Annual Meeting, San Diego, USA (Jing Yi Lee, Tun Kiat Ko)

  • 02 April 2024 : Collaborative research agreement with Illumina

  • 01 Nov 2023: Poster Presentation, CTOS Annual Meeting, Dublin (Elizabeth Lee)​​

  • 15 Sep 2023 : MOU and RCA signed with Agilent Technologies, BioSyngen, BGI Research and MGI Tech

  • 14 June 2023 : Poster Presentation, ICML Lugano, Switzerland​

  • 14 April 2023 : Poster Presentation, AACR Annual Meeting, Florida, USA (Bavani Kannan)​​​​​

  • 20 Mar 2023 : ESMO Merit Award, ESMO Sarcoma and Rare Cancers Congress, Lugano, Switzerland​

  • 18 Mar 2023 : Co-organizer, Singapore Lymphoma Scientific Symposium 2023

  • 12 Dec 2022 : Oral abstract, ASH Annual Meeting, New Orleans, USA​​

  • 09 Dec 2022 : Invited presentation, Stem Cell Society Singapore (SCSS) Symposium (Nimmi Baby)

  • 17 Nov 2022 : Oral paper, CTOS Annual Meeting, Vancouver, Canada (Jing Yi Lee)​

  • 19 Aug 2022 : Invited speech, 6th International BRCA Forum, Singapore​​

  • 19 Aug 2022 : Collaborative research agreement with Scinnohub Pharmaceutical

  • 19 Aug 2022 : Collaborative research agreement with MGI Tech

  • 04 Aug 2022 : Collaborative research agreement with Twist Bioscience

  • 16 Jun 2022 : Best Oral Presentation, International Congress of the Asian Oncology Society (AOS 2022), South Korea (Tun Kiat Ko)​

  • 12 Apr 2022 : Invited Oral Presentation at Major Symposium, AACR Annual Meeting, New Orleans, US

  • 22 Feb 2022 : Publication on circulating tumor DNA mutations in progressive gastrointestinal stromal tumors, Frontiers in Oncology

  • 17 Feb 2022 : Travel Award for Poster abstract at Japanese Society of Medical Oncology Annual Meeting, Japan (Elizabeth Lee)​​

  • ​​12 Jan 2022 : Commercial launch of the UNITED NGS Assay (Lucence) for Asian prevalent cancers at the NCCS

  • 21 Oct 2021 : Collaborative research agreement with STEMCELL Technologies

  • 01 Sep 2021 : Collaborative research agreement with SymBio Pharmaceuticals on EBV-positive lymphomas

  • 01 Sep 2021 : Official launch of Cancer Discovery Hub!

Featured Publications

Scientific publications supported by the Cancer Discovery Hub

High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population NPJ Precision Oncology. 2025

Nov, 2025

Advancements in next-generation sequencing have facilitated tumour-agnostic approaches for cancer therapy. Here, we demonstrate the clinical utility of molecularly guided tumour-agnostic precision medicine in an Asian cohort, leveraging an Asian-centric DNA/RNA comprehensive genomic profiling (CGP) panel. A total of 1166 tissue samples encompassing 29 cancer types underwent real-world CGP testing. Actionable biomarkers were identified in 62.3% of samples, including 1291 (4.7%) somatic variants potentially targetable by regulatory-approved therapies. At least one tumour-agnostic biomarker, including high tumour mutation burden (TMB-high), microsatellite instability (MSI-high), NTRK/RET fusions, and BRAF V600E was identified in 98 samples across 26 cancer types (8.4%). ERBB2 amplification was identified in 42 samples (3.6%) and was most frequently detected in breast (15.0%), followed by endometrial (11.8%) and ovarian tumours (8.9%). Homologous recombination deficiency (HRD) was observed in 407 samples (34.9%). The high prevalence of actionable biomarkers underscores the significance of CGP in facilitating precision medicine in an Asian setting.

bottom of page